Key Highlights

  • The BLA submission for miv-cel in stiff person syndrome was completed in the fourth quarter.
  • Cash and available-for-sale marketable securities were USD 170.6 million.
  • General and administrative expenses rose USD 7.6 million, or 92%, in the quarter.
  • Net loss for the nine months ended September 30, 2026 was USD 120.0 million.

Kyverna Therapeutics (NASDAQ:KYTX) reported third-quarter 2026 loss per share of USD 0.68, against an estimate of USD 0.69. The company's lead product candidate, mivocabtagene autoleucel, or miv-cel, also known as KYV-101, is advancing through late-stage clinical development. The company is focused on its neuroimmunology CAR T franchise, which includes evaluating miv-cel in stiff person syndrome and generalized myasthenia gravis.

Regulatory and Clinical Progress

The filing states that the company initiated the rolling BLA submission of miv-cel in stiff person syndrome in the second quarter of 2026 and completed it in the fourth quarter of 2026. It is seeking priority review under the Regenerative Medicine Advanced Therapy designation. In anticipation of a potential FDA approval and commercial launch in 2027, the company is progressing launch readiness activities, including targeted site activation engagements with CAR-T experts.

In stiff person syndrome, the company completed a registrational 26-patient Phase 2 trial, KYSA-8. It presented positive primary analysis results at the 2026 American Academy of Neurology Annual Meeting in April 2026, and one-year follow-up data at MS Toronto 2026 in October 2026. In the primary analysis, miv-cel achieved the primary and all secondary endpoints, demonstrating statistically significant, durable clinical benefit at 16 weeks, with Reversal of disability scores.

Expenses and Cash Flow

General and administrative expenses increased USD 7.6 million, or 92%, in the third quarter. The filing attributes this primarily to a USD 3.4 million increase in personnel-related expenses, including a USD 0.9 million increase in stock-based compensation from increased headcount. Professional services expenses increased USD 2.4 million and overhead expenses increased USD 1.3 million to support commercial readiness and market access activities.

Net cash used in Operating Activities for the nine months ended September 30, 2026 was USD 117.3 million. It consisted primarily of a net loss of USD 120.0 million and a USD 9.6 million net change in operating Assets and liabilities, partly offset by non-cash charges of USD 12.3 million. Those charges included USD 10.3 million of stock-based compensation, USD 1.3 million of non-cash Lease expense, USD 1.1 million of Depreciation and amortization and USD 0.5 million of asset impairment.

Net cash provided by financing activities was USD 10.5 million, against USD 0.4 million. Cash, cash equivalents and restricted cash fell by USD 92.3 million to USD 32.4 million, with cash and cash equivalents of USD 31.8 million and restricted cash of USD 0.6 million.

Liquidity, Securities and Equity

As of September 30, 2026, the company had cash and cash equivalents and available-for-sale marketable securities of USD 170.6 million. Marketable securities had a Fair Value of USD 277.3 million at amortized cost of USD 277.2 million as presented in the filing's table, including U.S. Government Bonds of USD 45.4 million. The filing states that the cash and securities, together with term loans available under a Loan Facility with Oxford Finance, are sufficient to fund the operating plan for at least 12 months from the date of the report.

As of September 30, 2026, USD 200.0 million remained available and unallocated under the 2026 registration statement, and USD 90.7 million remained available and allocated for sale under the at-the-market facility. Unvested restricted stock units were 1,919,385 at September 30, 2026, with a weighted-average grant date fair value of USD 7.73. The company paid USD 2.5 million to Kite in November 2025, and the remaining USD 3.8 million is recorded as current accrued license expense from a related party.

The reported items for the quarter are the completed BLA submission, general and administrative expenses, cash and securities of USD 170.6 million and the Liquidity statement. The company is listed on the Nasdaq Stock Market.